Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks

19Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

The economics of antibiotics can be improved by infectious diseases-specific clinical trial networks. While developers would still need to implement an independent phase 1 program as well as studies focused on highly resistant pathogens, standardized procedures in a network focused on usual drug resistance phenotype isolates would permit sharing of controls and would predictably generate high-quality pivotal data for product registration while creating cost and time savings in the range of 30%-40%. This would reduce economic barriers to antibiotic development and contribute to public health.

Cite

CITATION STYLE

APA

McDonnell, A., Rex, J. H., Goossens, H., Bonten, M., Fowler, V. G., & Dane, A. (2016). Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. Clinical Infectious Diseases, 63, S57–S59. https://doi.org/10.1093/cid/ciw244

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free